Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
Atea Pharmaceuticals (AVIR) filed a Form 4 on 24 Jun 2025 for director Bruno Lucidi covering transactions dated 20 Jun 2025.
- Common stock acquired: 29,600 shares were issued upon the full vesting and conversion of previously granted restricted stock units (RSUs) at a cost of $0, raising Lucidi’s direct holdings to 112,750 shares.
- New equity grants: (i) 29,600 RSUs that vest in a single tranche on the earlier of the next annual shareholder meeting or the first anniversary of grant; (ii) 41,200 stock options with a $3.25 exercise price, vesting in 12 equal monthly installments through 20 Jun 2026 and expiring on 19 Jun 2035.
- No open-market purchases or sales were reported; all activity reflects equity incentive awards and conversions.
The filing indicates continued insider equity ownership alignment, with a modest increase in direct share count and fresh long-term option incentives.
A Form 4 filed for Atea Pharmaceuticals, Inc. (AVIR) discloses that director Howard Berman received a new equity incentive award on 20 June 2025. The filing reports the grant of a stock option to purchase 164,800 shares of common stock at an exercise price of $3.25 per share. The option vests in 36 equal monthly installments beginning on the grant date and will be fully vested on 20 June 2028. It carries an expiration date of 19 June 2035. No acquisitions or dispositions of common shares were reported in Table I; the entire award is recorded in Table II as a derivative security held directly (Form D ownership). Following the grant, Berman’s reported beneficial ownership consists of 164,800 derivative securities tied to common stock. The transaction is coded “A,” indicating an award rather than a market purchase or sale.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) filed an 8-K summarising the results of its 20 June 2025 Annual Meeting of Stockholders.
- Quorum: 74,981,407 shares (≈87.6 % of outstanding) were represented in person or by proxy.
- Director elections (Class II, terms expiring 2028):
- Bruno Lucidi - 46,640,587 FOR / 12,559,084 WITHHOLD / 15,781,736 broker non-votes.
- Polly Murphy, DVM, PhD - 41,184,263 FOR / 18,015,408 WITHHOLD / 15,781,736 broker non-votes.
- Bruce Polsky, MD - 46,597,653 FOR / 12,602,018 WITHHOLD / 15,781,736 broker non-votes.
- Auditor ratification: KPMG LLP re-appointed for FY 2025 with 73,766,274 FOR, 1,192,659 AGAINST, 22,474 ABSTAIN; no broker non-votes.
- Say-on-pay (advisory): 46,450,302 FOR, 12,107,029 AGAINST, 642,340 ABSTAIN, 15,781,736 broker non-votes.
All three proposals passed. No other material business was disclosed in the filing.